[go: up one dir, main page]

WO2007089880A3 - Method to detect breast cancer cells - Google Patents

Method to detect breast cancer cells Download PDF

Info

Publication number
WO2007089880A3
WO2007089880A3 PCT/US2007/002716 US2007002716W WO2007089880A3 WO 2007089880 A3 WO2007089880 A3 WO 2007089880A3 US 2007002716 W US2007002716 W US 2007002716W WO 2007089880 A3 WO2007089880 A3 WO 2007089880A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
cancer cells
detect breast
detect
receptor expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/002716
Other languages
French (fr)
Other versions
WO2007089880A2 (en
Inventor
Vassilios Papadopoulos
Martine Culty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Priority to AU2007211251A priority Critical patent/AU2007211251A1/en
Publication of WO2007089880A2 publication Critical patent/WO2007089880A2/en
Publication of WO2007089880A3 publication Critical patent/WO2007089880A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A quantitative method to detect variant and total peripheral-type benzodiazepine receptor expression is provided.
PCT/US2007/002716 2006-01-31 2007-01-31 Method to detect breast cancer cells Ceased WO2007089880A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007211251A AU2007211251A1 (en) 2006-01-31 2007-01-31 Method to detect breast cancer cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76371006P 2006-01-31 2006-01-31
US60/763,710 2006-01-31

Publications (2)

Publication Number Publication Date
WO2007089880A2 WO2007089880A2 (en) 2007-08-09
WO2007089880A3 true WO2007089880A3 (en) 2007-11-15

Family

ID=38222452

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/002716 Ceased WO2007089880A2 (en) 2006-01-31 2007-01-31 Method to detect breast cancer cells

Country Status (2)

Country Link
AU (1) AU2007211251A1 (en)
WO (1) WO2007089880A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US10591391B2 (en) 2006-06-14 2020-03-17 Verinata Health, Inc. Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US10704090B2 (en) 2006-06-14 2020-07-07 Verinata Health, Inc. Fetal aneuploidy detection by sequencing

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2718464A1 (en) * 2011-06-06 2014-04-16 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo
EP3304041B1 (en) 2015-05-26 2021-03-10 IncellDx, Inc. Methods of assessing cellular breast samples and compositions for use in practicing the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049316A2 (en) * 1998-03-25 1999-09-30 Georgetown University Medical Center Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049316A2 (en) * 1998-03-25 1999-09-30 Georgetown University Medical Center Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DE CREMOUX P ET AL: "Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AUG 2000, vol. 6, no. 8, August 2000 (2000-08-01), pages 3117 - 3122, XP002449903, ISSN: 1078-0432 *
HAN ZEQIU ET AL: "Expression of peripheral benzodiazepine receptor (PBR) in human tumors: Relationship to breast, colorectal, and prostate tumor progression.", JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, vol. 23, no. 2-3, May 2003 (2003-05-01), pages 225 - 238, XP009089189 *
HARDWICK M ET AL: "Peripheral - type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 4, 15 February 1999 (1999-02-15), pages 831 - 842, XP002114583, ISSN: 0008-5472 *
HARDWICK M ET AL: "Peripheral-type benzodiazepine receptor levels correlate with the ability of human breast cancer MDA-MB-231 cell line to grow in SCID mice.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 1 NOV 2001, vol. 94, no. 3, 1 November 2001 (2001-11-01), pages 322 - 327, XP002449906, ISSN: 0020-7136 *
HARDWICK MATTHEW ET AL: "Peripheral-type benzodiazepine receptor (PBR) gene amplification in MDA-MB-231 aggressive breast cancer cells.", CANCER GENETICS AND CYTOGENETICS NOV 2002, vol. 139, no. 1, November 2002 (2002-11-01), pages 48 - 51, XP002449905, ISSN: 0165-4608 *
KURUMAJI A ET AL: "No association of two missense variations of the benzodiazepine receptor (peripheral) gene and mood disorders in a Japanese sample.", AMERICAN JOURNAL OF MEDICAL GENETICS 8 MAR 2001, vol. 105, no. 2, 8 March 2001 (2001-03-08), pages 172 - 175, XP002449910, ISSN: 0148-7299 *
LARA O ET AL: "Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation", EXPERIMENTAL HEMATOLOGY, NEW YORK, NY, US, vol. 32, no. 10, October 2004 (2004-10-01), pages 891 - 904, XP004613157, ISSN: 0301-472X *
RING A ET AL: "Circulating tumour cells in breast cancer", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 5, no. 2, February 2004 (2004-02-01), pages 79 - 88, XP004808305, ISSN: 1470-2045 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US11674176B2 (en) 2006-06-14 2023-06-13 Verinata Health, Inc Fetal aneuploidy detection by sequencing
US9273355B2 (en) 2006-06-14 2016-03-01 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US10591391B2 (en) 2006-06-14 2020-03-17 Verinata Health, Inc. Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US9017942B2 (en) 2006-06-14 2015-04-28 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US11781187B2 (en) 2006-06-14 2023-10-10 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9347100B2 (en) 2006-06-14 2016-05-24 Gpb Scientific, Llc Rare cell analysis using sample splitting and DNA tags
US11261492B2 (en) 2006-06-14 2022-03-01 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US10704090B2 (en) 2006-06-14 2020-07-07 Verinata Health, Inc. Fetal aneuploidy detection by sequencing
US10041119B2 (en) 2006-06-14 2018-08-07 Verinata Health, Inc. Methods for the diagnosis of fetal abnormalities
US10155984B2 (en) 2006-06-14 2018-12-18 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US10435751B2 (en) 2006-06-14 2019-10-08 Verinata Health, Inc. Methods for the diagnosis of fetal abnormalities
US8682594B2 (en) 2008-09-20 2014-03-25 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US10669585B2 (en) 2008-09-20 2020-06-02 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9404157B2 (en) 2008-09-20 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9353414B2 (en) 2008-09-20 2016-05-31 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8296076B2 (en) 2008-09-20 2012-10-23 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuoploidy by sequencing
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US12054777B2 (en) 2008-09-20 2024-08-06 The Board Of Trustees Of The Leland Standford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing

Also Published As

Publication number Publication date
AU2007211251A1 (en) 2007-08-09
WO2007089880A2 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
WO2007089880A3 (en) Method to detect breast cancer cells
IL256247B (en) Activin-actrii antagonists and uses for increasing red blood cell levels
EP1999767B8 (en) Energy collection
GB0622393D0 (en) Back contacted solar cell
MX2009005724A (en) Estrogen/ serm and estrogen/ progestin bi-layer tablets.
GB2440434B (en) Fuel cells
IL195500A0 (en) Patches, systems, and methods for non-invasive glucose measurement
GB2440435B (en) Fuel cells
EP2109668A4 (en) Human cancer stem cells
ZA200805609B (en) Mesenchymal stem cells expressing TNF-α receptor
GB0605878D0 (en) Fuel cells
ZA200808029B (en) Devices and methods for detecting cells and other analytes
EP4328589A3 (en) Cancer biomarkers
EP1781328A4 (en) Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
IL209907A0 (en) Methods and devices for independent evaluation of cell integrity, changes and origin in chip design for production workflow
IL197888A0 (en) Integrated biomass energy system
EP2008107A4 (en) Detection of steroid receptors on circulating carcinoma cells and treatment
GB0616045D0 (en) Blood cell separation
GB0605393D0 (en) Composite menbranes for electrochemical cells
GB0702007D0 (en) Anaerobic digester
CA130132S (en) Toilet bowl for vacuum waste system
CA118203S (en) Straw chopper
EP2076520A4 (en) Integrated collection, analysis, and recycling method
HK1123356A (en) Detection of steroid receptors on circulating carcinoma cells and treatment
NL2002092C (en) Mammography-apparatus and method for screening the occurrence of malignant cells.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007211251

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007211251

Country of ref document: AU

Date of ref document: 20070131

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 07717158

Country of ref document: EP

Kind code of ref document: A2